Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.35 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.35 |
| ▸ | B3GNT2 | Q9NY97 | 3/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2312582 | 0.87 | POLB (0.48) | POLBESR1MDM2MEN1CYP1A2 | |
| SCHEMBL2312588 | 0.87 | POLB (0.48) | POLBESR1MDM2MEN1CYP1A2 | |
| SCHEMBL20840412 | 0.83 | POLB (0.50) | POLBMDM2MEN1CYP1A2KMT2A | |
| SCHEMBL2308145 | 0.78 | POLB (0.57) | POLBMDM2MEN1CYP1A2KMT2A | |
| SCHEMBL19410170 | 0.78 | POLB (0.57) | POLBMDM2MEN1CYP1A2KMT2A | |
| SCHEMBL2308151 | 0.78 | POLB (0.57) | POLBMDM2MEN1CYP1A2KMT2A | |
| SCHEMBL27776802 | 0.75 | POLB (0.50) | POLBMDM2MEN1CYP1A2KMT2A | |
| SCHEMBL22502544 | 0.75 | MDM2 (0.39) | POLBESR1MDM2MEN1KMT2A | |
| SCHEMBL29502465 | 0.75 | B3GNT2 (0.39) | ESR1MDM2MEN1KMT2AB3GNT2 | |
| SCHEMBL21996991 | 0.75 | B3GNT2 (0.39) | ESR1MDM2MEN1KMT2AB3GNT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624044-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260085075-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4624467-A2 | PROTEIN DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| US-20230115184-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20230115184-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-11623932-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-04-11 | — | — | US | disclosed |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
| US-20210238193-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20210238193-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
| WO-2020251971-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020251971-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| EP-3684365-A1 | PROTEIN DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2020-07-29 | — | — | EP | disclosed |
| WO-2019060742-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC (US) | 2019-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230115184-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | POLB 3638/4885ESR1 2358/4885MDM2 1/4885 |
| US-20210238193-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | POLB 3638/4885ESR1 2358/4885MDM2 1/4885 |
| US-11623932-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | POLB 3638/4885ESR1 2358/4885MDM2 1/4885 |
| US-12624044-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCC1, SMARCA2 | POLB 451/4885ESR1 2055/4885MDM2 148/4885 |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | POLB 456/4885ESR1 3111/4885MDM2 123/4885 |
| US-20260085075-A1 | PROTEIN DEGRADERS AND USES THEREOF | NR2C2, SRR, NCOR2 | POLB 2281/4885ESR1 1162/4885MDM2 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.